TY - JOUR
T1 - Multiple sclerosis treatment and melanoma development
AU - Carbone, Maria Luigia
AU - Lacal, Pedro Miguel
AU - Messinese, Serena
AU - De Giglio, Laura
AU - Pozzilli, Carlo
AU - Persechino, Severino
AU - Mazzanti, Cinzia
AU - Failla, Cristina Maria
AU - Pagnanelli, Gianluca
N1 - Funding Information:
Funding: This work was supported by grants of the Italian Ministry of Health, “Ricerca Corrente” RC3.3-2018-2638151; RC3.5-2019-2755065. M.L.C. is the recipient of a fellowship of “Fondazione Veronesi”.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4/2
Y1 - 2020/4/2
N2 - Therapy of multiple sclerosis (MS) with disease-modifying agents such as natalizumab or fingolimod has been associated with the development of cutaneous melanoma. Here we briefly revise literature data and report of a case of a 48-year old woman who developed a melanoma and several atypical naevi after sub sequential treatment with natalizumab (1 year) and fingolimod (7 years). By immunohistochemistry we observed the presence of T cells and leukocyte infiltration as well as of vascular endothelial growth factor (VEGF)-A expression in the patient melanoma biopsy. Then, we analyzed proliferation, migration and VEGF-A expression in three melanoma cell lines and found out that both natalizumab and fingolimod inhibited tumor cell proliferation but promoted or blocked cell migration depending on the cell line examined. VEGF-A secretion was augmented in one melanoma cell line only after fingolimod treatment. In conclusion, our in vitro data do not support the hypothesis of a direct action of natalizumab or fingolimod on melanoma progression but acting on the tumor microenvironment these treatments could indirectly favor melanoma evolution.
AB - Therapy of multiple sclerosis (MS) with disease-modifying agents such as natalizumab or fingolimod has been associated with the development of cutaneous melanoma. Here we briefly revise literature data and report of a case of a 48-year old woman who developed a melanoma and several atypical naevi after sub sequential treatment with natalizumab (1 year) and fingolimod (7 years). By immunohistochemistry we observed the presence of T cells and leukocyte infiltration as well as of vascular endothelial growth factor (VEGF)-A expression in the patient melanoma biopsy. Then, we analyzed proliferation, migration and VEGF-A expression in three melanoma cell lines and found out that both natalizumab and fingolimod inhibited tumor cell proliferation but promoted or blocked cell migration depending on the cell line examined. VEGF-A secretion was augmented in one melanoma cell line only after fingolimod treatment. In conclusion, our in vitro data do not support the hypothesis of a direct action of natalizumab or fingolimod on melanoma progression but acting on the tumor microenvironment these treatments could indirectly favor melanoma evolution.
KW - Fingolimod
KW - Melanoma
KW - Natalizumab
KW - VEGF-A
UR - http://www.scopus.com/inward/record.url?scp=85083968209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083968209&partnerID=8YFLogxK
U2 - 10.3390/ijms21082950
DO - 10.3390/ijms21082950
M3 - Article
C2 - 32331328
AN - SCOPUS:85083968209
VL - 21
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 8
M1 - 2950
ER -